[¹⁴C]Etelcalcetide
Phase 1Completed 0 watching 0 views this week💤 Quiet
32
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Secondary Hyperparathyroidism in Patients With ESRD on Hemodialysis
Conditions
Secondary Hyperparathyroidism in Patients With ESRD on Hemodialysis
Trial Timeline
Feb 7, 2014 → Aug 15, 2014
NCT ID
NCT02054572About [¹⁴C]Etelcalcetide
[¹⁴C]Etelcalcetide is a phase 1 stage product being developed by Amgen for Secondary Hyperparathyroidism in Patients With ESRD on Hemodialysis. The current trial status is completed. This product is registered under clinical trial identifier NCT02054572. Target conditions include Secondary Hyperparathyroidism in Patients With ESRD on Hemodialysis.
Hype Score Breakdown
Clinical
10
Activity
5
Company
9
Novelty
3
Community
2
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02054572 | Phase 1 | Completed |
Competing Products
20 competing products in Secondary Hyperparathyroidism in Patients With ESRD on Hemodialysis
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| ASP7991 + Cinacalcet + Placebo | Astellas Pharma | Phase 2 | 52 |
| Fycompa | Eisai | Pre-clinical | 23 |
| Fycompa | Eisai | Pre-clinical | 23 |
| KHK7580 + KRN1493 | Kyowa Kirin | Phase 2/3 | 65 |
| KHK7580 | Kyowa Kirin | Phase 1 | 33 |
| KHK7580 | Kyowa Kirin | Phase 3 | 77 |
| KHK7580 | Kyowa Kirin | Phase 3 | 77 |
| Cinacalcet HCl | Kyowa Kirin | Approved | 85 |
| KHK7580 + Cinacalcet Hydrochloride | Kyowa Kirin | Phase 3 | 77 |
| Placebo + KHK7580 low dose + KHK7580 middle dose + KHK7580 high dose + KRN1493 | Kyowa Kirin | Phase 2 | 52 |
| dirucotide + Placebo | Eli Lilly | Phase 2/3 | 65 |
| dirucotide | Eli Lilly | Phase 2/3 | 65 |
| Paricalcitol + Calcitriol | AbbVie | Pre-clinical | 23 |
| paricalcitol + maxacalcitol + paricalcitol placebo + maxacalcitol placebo | AbbVie | Phase 3 | 77 |
| Paricalcitol + Calcifediol | AbbVie | Approved | 85 |
| Paricalcitol + Darbepoetin alfa | AbbVie | Approved | 85 |
| Birabresib Dose 20 mg | Merck | Phase 1 | 33 |
| Remibrutinib (blinded) + Placebo + Remibrutinib (Open label) | Novartis | Phase 3 | 77 |
| Ranibizumab | Novartis | Approved | 85 |
| BAF312 + Baseline disease modifying therapies (DMTs) + BNT162 + mRNA-1273 | Novartis | Approved | 85 |